Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Sarah B Rippy"'
Autor:
Heather L Gardner, Sarah B Rippy, Misty D Bear, Kim L Cronin, Heather Heeb, Holly Burr, Claire M Cannon, Kumar V Penmetsa, Srikant Viswanadha, Swaroop Vakkalanka, Cheryl A London
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0195357 (2018)
RV1001 is a novel, potent, and selective PI3Kδ inhibitor. The purpose of this study was to evaluate the safety and efficacy of RV1001 in canine Non-Hodgkin lymphoma (NHL).Inhibition of endogenous pAKT by RV1001 in primary canine NHL cells was determ
Externí odkaz:
https://doaj.org/article/2cde8c7101d8458aaeb72cfb3d0632c4
Autor:
William Tod Drost, Cheryl A. London, Eric M. Green, Sarah B. Rippy, Emma E. Warry, Roberta F. Portela, Juan Peng, Heather L. Gardner, Sandra M. Nguyen, Dennis J. Chew, Eric T. Hostnik
Publikováno v:
BMC Veterinary Research
Background Effective therapies for transitional cell carcinoma (TCC) are limited, with objective response rates to most chemotherapeutic regimens below 20%. The purpose of this study was to investigate the biologic activity of combined toceranib phos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::638da74a9b5849c56535a2377f599502
https://doi.org/10.1186/s12917-016-0882-6
https://doi.org/10.1186/s12917-016-0882-6
Autor:
Linda Crew, Andrew J. Garton, Sarah B. Rippy, Cheryl A. London, Gerald McMahon, Richard Gedrich, Lori Lopresti-Morrow, Theresa LaVallee, Krista M. D. La Perle, Heather L. Gardner, G. S. Post
Purpose: KTN0158 is a novel anti-KIT antibody that potently inhibits wild-type and mutant KIT. This study evaluated the safety, biologic activity, and pharmacokinetic/pharmacodynamics profile of KTN0158 in dogs with spontaneous mast cell tumors (MCT)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e75f8b5658f194d1471a79df29e75ae5
https://europepmc.org/articles/PMC5418113/
https://europepmc.org/articles/PMC5418113/
Autor:
Sarah B. Rippy, Claire M Cannon, Srikant Viswanadha, Kim L. Cronin, Heather L. Gardner, Cheryl A. London, Swaroop Vakkalanka, Kumar V. Penmetsa, Holly Burr, Heather Heeb, Misty D. Bear
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0195357 (2018)
PLoS ONE
PLoS ONE
Background RV1001 is a novel, potent, and selective PI3Kδ inhibitor. The purpose of this study was to evaluate the safety and efficacy of RV1001 in canine Non-Hodgkin lymphoma (NHL). Methods and results Inhibition of endogenous pAKT by RV1001 in pri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f58646b077efe12ad6c929e1d20a547f
https://doi.org/10.1371/journal.pone.0195357
https://doi.org/10.1371/journal.pone.0195357
Autor:
Theresa LaVallee, Sarah B. Rippy, Heather L. Gardner, Richard Gedrich, Cheryl A. London, Linda Crew, Neal Janson, G. S. Post, William C. Kisseberth
Publikováno v:
Molecular Cancer Therapeutics. 14:C167-C167
Background: KTN0158 is a novel humanized anti-KIT IgG1 monoclonal antibody that binds canine, feline, non-human primate and human KIT with high affinity. KTN0158 potently inhibits wild-type and some oncogenic variants of KIT in vitro and modulates ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ca5f917b3448d302117d82c5c7160c2
https://doi.org/10.1158/1535-7163.targ-15-c167
https://doi.org/10.1158/1535-7163.targ-15-c167
Autor:
Chaohua Zhang, Cheryl A. London, Noriaki Tatsuta, Andrew Sonderfan, Jun Jiang, Donald L. Smith, Luisa S. Ogawa, Vladimir Khazak, Teresa Przewloka, Igor Astsaturov, John Chu, Jaime Acquaviva, David A. Proia, Sarah B. Rippy, Richard C. Bates, Jim Sang, Dan Zhou, Takayo Inoue, Josephine Ye, Manuel Sequeira, Junyi Zhang, Suqin He, John-Paul Jimenez, Weiwen Ying, Dinesh Chimmanamada, Yuan Liu
Publikováno v:
Cancer Research. 75:4409-4409
Chemotherapeutic drugs have been a mainstay of cancer therapy for decades; however, their effectiveness is often hampered by inefficient drug exposures and undesirable toxicity to normal tissues. Here we report on a novel drug delivery system, termed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::814d52979a71c589cf175a5d67861b81
https://doi.org/10.1158/1538-7445.am2015-4409
https://doi.org/10.1158/1538-7445.am2015-4409
Autor:
Kim L. Cronin, Srikant Viswanadha, Misty D. Bear, Kumar V. Penmetsa, Andrew H. Abbo, Cheryl A. London, Swaroop Vakkalanka, Sarah B. Rippy
Publikováno v:
Cancer Research. 75:4700-4700
Background: Non-Hodgkin's lymphoma (NHL) is the most common cancer in dogs with over 70,000 new cases diagnosed each year. Evidence suggests that canine NHL is an excellent spontaneous large animal model of human NHL, particularly for the evaluation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d4407bd540033a8a3f0291bd421add6
https://doi.org/10.1158/1538-7445.am2015-4700
https://doi.org/10.1158/1538-7445.am2015-4700
Autor:
Roberta F. Portela, Heather L. Gardner, Sarah B. Rippy, Emma E. Warry, Eric T. Hostnik, Juan Peng, Dennis J. Chew, Eric M. Green, William Tod Drost, Cheryl A. London, Sandra M. Nguyen
Publikováno v:
BMC Veterinary Research. 12(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ee2349c4280b40cf17010f811710126